Health Sciences Acquisitions Corporation
Status: Deal Closed
U=S+W
W=S/2@11.5
IPO Proceeds, $M | $115.00M |
---|---|
IPO Date | May 10, 2019 |
CEO | Roderick Wong, MD |
Left Lead | Chardan |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 months |
IPO Sector |
Healthcare
Biopharma & medical technology in North America or Europe |
IPO Geography | North America/Europe |
Target Company | Immunovant |
Deal Announced | Oct 2, 2019 |
Deal Size, $M | $555.75M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Dec 16, 2019 |
Amendment Vote | TBD |
Closing Date | Dec 18, 2019 |
Formerly HSAC
IMVT
IMVTW
Price | $28.45 |
---|---|
Last closing price | $28.79 |
H/L, 52-week | $10.62 / $44.19 |
Volume, today | 210,868 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Health Sciences Acquisitions Corporation:
- Structure and cap table
- 9 directors & officers
- 29 filings and events
- 2 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Roderick Wong, MD | 41 | President, CEO & Chairman |
Naveen Yalamanchi, MD | 42 | EVP, CFO & Director |
Alice Lee, JD | 48 | VP of Operations, Secretary & Treasurer |
Stephanie A. Sirota | 44 | VP of Corporate Strategy & Corporate Communications |
Mark Schoenebaum, MD | 46 | Director |
Sukumar Nagendran, MD | 52 | Director |
Pedro Granadillo | 71 | Director |
George Migausky | 64 | Director |
Gotham Makker, MD | 45 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Deal
Sign in to view merger details and deal financials.